KR20260023529A - Nrf2 활성화 작용을 갖는 질소 함유 헤테로고리 화합물의 결정 - Google Patents
Nrf2 활성화 작용을 갖는 질소 함유 헤테로고리 화합물의 결정Info
- Publication number
- KR20260023529A KR20260023529A KR1020257042624A KR20257042624A KR20260023529A KR 20260023529 A KR20260023529 A KR 20260023529A KR 1020257042624 A KR1020257042624 A KR 1020257042624A KR 20257042624 A KR20257042624 A KR 20257042624A KR 20260023529 A KR20260023529 A KR 20260023529A
- Authority
- KR
- South Korea
- Prior art keywords
- crystal
- powder
- compound
- diffraction
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2023-100075 | 2023-06-19 | ||
| JP2023100075 | 2023-06-19 | ||
| PCT/JP2024/022040 WO2024262491A1 (ja) | 2023-06-19 | 2024-06-18 | Nrf2活性化作用を有する含窒素複素環化合物の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20260023529A true KR20260023529A (ko) | 2026-02-20 |
Family
ID=93935419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257042624A Pending KR20260023529A (ko) | 2023-06-19 | 2024-06-18 | Nrf2 활성화 작용을 갖는 질소 함유 헤테로고리 화합물의 결정 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4696692A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7904995B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20260023529A (cg-RX-API-DMAC7.html) |
| CN (1) | CN121152792A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2024314540A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL324833A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025014082A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202504613A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024262491A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
| US20190380992A1 (en) | 2014-12-04 | 2019-12-19 | Biogen Ma Inc. | Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| JOP20210030A1 (ar) | 2018-08-20 | 2021-02-16 | Janssen Pharmaceutica Nv | مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2 |
| KR102932313B1 (ko) | 2019-02-15 | 2026-02-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 활성화제로서 히드록시피리드옥사제핀 |
| CN114174289B (zh) | 2019-05-31 | 2025-03-07 | Ube株式会社 | 苯并三唑衍生物 |
| GB202005852D0 (en) | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
| CN114507181B (zh) | 2020-11-17 | 2024-03-26 | 中国医学科学院药物研究所 | 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用 |
| CR20240325A (es) | 2022-01-07 | 2024-11-22 | Chugai Pharmaceutical Co Ltd | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2 |
-
2024
- 2024-06-18 EP EP24825892.3A patent/EP4696692A1/en active Pending
- 2024-06-18 AU AU2024314540A patent/AU2024314540A1/en active Pending
- 2024-06-18 TW TW113122470A patent/TW202504613A/zh unknown
- 2024-06-18 KR KR1020257042624A patent/KR20260023529A/ko active Pending
- 2024-06-18 CN CN202480033461.0A patent/CN121152792A/zh active Pending
- 2024-06-18 IL IL324833A patent/IL324833A/en unknown
- 2024-06-18 WO PCT/JP2024/022040 patent/WO2024262491A1/ja not_active Ceased
- 2024-06-18 JP JP2025528066A patent/JP7904995B2/ja active Active
-
2025
- 2025-11-25 MX MX2025014082A patent/MX2025014082A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202504613A (zh) | 2025-02-01 |
| JP7904995B2 (ja) | 2026-08-13 |
| IL324833A (en) | 2026-01-01 |
| MX2025014082A (es) | 2026-01-07 |
| AU2024314540A1 (en) | 2025-11-27 |
| EP4696692A1 (en) | 2026-02-18 |
| JPWO2024262491A1 (cg-RX-API-DMAC7.html) | 2024-12-26 |
| CN121152792A (zh) | 2025-12-16 |
| WO2024262491A1 (ja) | 2024-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7773987B2 (ja) | スピロ環含有キナゾリン化合物 | |
| CN103694236B (zh) | 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物 | |
| CN109776445B (zh) | 苯并噁二唑类化合物及其制备方法和医药用途 | |
| CN105884780B (zh) | 多环化合物、其药物组合物及应用 | |
| CN114907387A (zh) | 嘧啶并吡咯类kras抑制剂及其制备方法与应用 | |
| TWI923765B (zh) | 異喹啉酮類化合物及其用途 | |
| EP3325490B1 (en) | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists | |
| CN112430234A (zh) | 一种新型kras g12c蛋白抑制剂及其制备方法和用途 | |
| WO2015127872A1 (zh) | 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 | |
| JPWO2016039408A1 (ja) | 複素環化合物 | |
| CN103923085B (zh) | 具有刺猬通路拮抗剂活性的吡啶杂环化合物及其用途 | |
| CN108727295A (zh) | 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途 | |
| AU2018340505A1 (en) | Novel heterocyclic compounds as modulators of mGluR7 | |
| CA2952230C (en) | Pyrimidine compounds and methods using the same | |
| CA3029911C (en) | Antimetastatic 2h-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents | |
| TW201704227A (zh) | 新穎雜芳基胺基-3-吡唑衍生物及其藥理學上可容許之鹽 | |
| CN102757448B (zh) | 大环类激酶抑制剂化合物、制备方法及其作为药物的应用 | |
| CN104334528A (zh) | (2-杂芳基氨基)琥珀酸衍生物 | |
| KR100902145B1 (ko) | 3,4-디히드로퀴나졸린 유도체 및 그를 포함하는 항암제조성물 | |
| CA3291766A1 (en) | Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect | |
| AU2024314540A1 (en) | Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect | |
| JP2016000700A (ja) | 2−アミノ置換ピリジン誘導体 | |
| US20200207782A1 (en) | Chemically activated water-soluble prodrug | |
| JP7620711B2 (ja) | アミドオキサゾール系化合物 | |
| WO2026092276A1 (zh) | 用于抑制ptpn蛋白的化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |